Table III.

Standardized incidence ratios stratified by sex, race/ethnicity, and stage of disease

Characteristics	Observed, n	Expected, n	SIR	95% CI lower limit	95% CI upper limit	Mean age at diagnosis of MF, years	Mean age at diagnosis of second malignancy, years	Latency, years*
Total	511	50.35	10.15†	9.29	11.07	63.33	68.14	4.81
Sex
Male	310	35.94	8.62†	7.69	9.64	64.28	68.84	4.56
Female	201	14.41	13.95†	12.09	16.02	61.86	67.05	5.19
Race/ethnicity
Non-Hispanic white	369	40.41	9.13†	8.22	10.11	64.94	69.67	4.73
Non-Hispanic black	73	5.20	14.03†	11.00	17.64	56.35	61.59	5.24
Non-Hispanic American Indian/Alaska Native	3	0.12	24.43†	5.04	71.39	68.5	73.81	5.31
Non-Hispanic Asian or Pacific Islander	34	2.02	16.87†	11.68	23.57	63.92	68.4	4.48
Hispanic (all races)	32	2.42	13.24†	9.06	18.69	59.08	64.55	5.47
Stage
IA	152	11.46	13.26†	11.24	15.54	62.99	67.35	4.36
IB	34	1.84	18.51†	12.82	25.87	62.46	63.73	1.27
IIA	3	0.14	20.99†	4.33	61.34	57.45	62	4.55
IIB	20	1.53	13.10†	8.00	20.22	66.77	71.78	5.01
IIIA	6	0.41	14.71†	5.40	32.03	70.07	70.43	0.36
IIIB	3	0.05	65.78†	13.57	192.25	66.89	67.89	1.00
IVNOS	3	0.20	14.96†	3.08	43.71	61.96	69.54	7.58
IVA	4	0.01	281.33†	76.65	720.31	66.67	67.17	0.50
IVB	5	0.11	43.56†	14.14	101.66	73.37	75.23	1.86
Unknown stage	90	6.53	13.78†	11.08	16.93	63.77	68.08	4.31
Blank(s)	191	28.06	6.81†	5.88	7.84	62.81	69.04	6.23

CI, Confidence interval; MF, mycosis fungoides; NOS, not otherwise specified; SIR, standardized incidence ratio (data for malignancies that did not occur in the sample set are omitted).

^*The time between diagnosis of MF and diagnosis of a second primary malignancy.

^†P < .05.